MLH1 Methylation Analysis Kit
£1,474.00
The geneMAP™ MLH1 Methylation Analysis Kit is designed to detect and quantitatively analyze the methylation status of the MLH1 gene promoter, utilizing methylation-specific PCR (MSP) and multiplex real-time PCR technology. This kit, compatible with FAM and VIC/HEX two-color real-time PCR instruments and CE-IVD certified, offers superior analytical sensitivity and specificity for assessing MLH1 methylation. This analysis is crucial for diagnosing Lynch Syndrome, an autosomal dominant cancer syndrome associated with a high risk of endometrial and colorectal cancers due to mutations in DNA mismatch repair (MMR) genes, including MLH1.
The geneMAP™ MLH1 Methylation Analysis Kit is designed to detect and quantitatively analyze the methylation status of the MLH1 gene promoter, utilizing methylation-specific PCR (MSP) and multiplex real-time PCR technology. This kit, compatible with FAM and VIC/HEX two-color real-time PCR instruments and CE-IVD certified, offers superior analytical sensitivity and specificity for assessing MLH1 methylation. This analysis is crucial for diagnosing Lynch Syndrome, an autosomal dominant cancer syndrome associated with a high risk of endometrial and colorectal cancers due to mutations in DNA mismatch repair (MMR) genes, including MLH1.
- Methylation-Specific PCR: Enhances detection sensitivity and specificity for MLH1 gene promoter methylation.
- Multiplex Real-time PCR Technology: Enables fast, efficient, and quantitative methylation analysis.
- Instrument Compatibility: Optimized for use with FAM and VIC/HEX two-color real-time PCR instruments, providing flexibility for different laboratory settings.
- CE-IVD Certification: Meets European standards for in vitro diagnostic medical devices, affirming its reliability and quality.
- Accurate Quantification of Methylation Levels: Delivers precise calculation of methylation percentage, offering valuable insights into MLH1 promoter methylation status.
- Early Diagnosis of Lynch Syndrome: Facilitates the identification of Lynch Syndrome in patients with sentinel cancers, allowing for timely surveillance and intervention for associated cancers.
- Impact on Treatment and Surveillance: Identifying MLH1 methylation can guide personalized treatment plans and surveillance strategies for patients and at-risk family members.
- Diagnosis of Lynch Syndrome: Essential for assessing MLH1 methylation as a potential marker of Lynch Syndrome, particularly in patients with endometrial and colorectal cancers.
- Cancer Surveillance and Prevention: Aids in the surveillance and prevention strategies for individuals diagnosed with Lynch Syndrome and their family members, by identifying the methylation status of the MLH1 gene.
- Technology: Utilizes methylation-specific and multiplex real-time PCR for the detection and quantification of MLH1 promoter hypermethylation.
- Compatibility: Suitable for FAM and VIC/HEX two-color real-time PCR instruments.
- Quantitative Analysis: Offers quantitative methylation analysis, calculating the methylation level percentage.
- Certification: Carries the CE-IVD mark, indicating compliance with EU regulations for in vitro diagnostic use.
Why Choose Clent
We strive to enable our customers to focus on the results of their work, rather than the tools they use. Need to speak with a member of our team? Get in touch today.
